Clinical reasoning and prevention of cardiovascular disease

被引：2
作者：
Allan, Sniderman [1 ]
Pencina, Michael [2 ]
Thanassoulis, George [1 ]
机构：
[1] McGill Univ Hlth Ctr, Dept Med, Mike & Valeria Rosenbloom Ctr Cardiovasc Prevent, Montreal, PQ, Canada
[2] Duke Univ, Sch Med Biostat & Bioinformat, DCRI, Dept Lab Med, Durham, NC USA
来源：
JOURNAL OF CLINICAL LIPIDOLOGY | 2021年 / 15卷 / 03期
关键词：
NON-HDL CHOLESTEROL; APOLIPOPROTEIN-B; RISK; LDL; LIPOPROTEINS; METAANALYSIS; NUMBER; ERA;
D O I：
10.1016/j.jacl.2021.04.001
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：394 / 398
页数：5
相关论文
共 33 条
  • [1] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [2] The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity
    Boren, Jan
    Williams, Kevin Jon
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (05) : 473 - 483
  • [3] Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
    Cole, Thomas G.
    Contois, John H.
    Csako, Gyorgy
    McConnell, Joseph P.
    Remaley, Alan T.
    Devaraj, Sridevi
    Hoefner, Daniel M.
    Mallory, Tonya
    Sethi, Amar A.
    Warnick, G. Russell
    [J]. CLINICAL CHEMISTRY, 2013, 59 (05) : 752 - 770
  • [4] Grundy SM, 2019, CIRCULATION, V139, pE1082, DOI 10.1161/CIR.0000000000000625
  • [5] Johannesen C.D., J AM COLL CARDIOL
  • [6] The clinical utility of apoB versus LDL-C/non-HDL-C
    Kohli-Lynch, Ciaran N.
    Thanassoulis, George
    Moran, Andrew E.
    Sniderman, Allan D.
    [J]. CLINICA CHIMICA ACTA, 2020, 508 : 103 - 108
  • [7] Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
    Langlois, Michel R.
    Nordestgaard, Borge G.
    Langsted, Anne
    Chapman, M. John
    Aakre, Kristin M.
    Baum, Hannsjoerg
    Boren, Jan
    Bruckert, Eric
    Catapano, Alberico
    Cobbaert, Christa
    Collinson, Paul
    Descamps, Olivier S.
    Duff, Christopher J.
    von Eckardstein, Arnold
    Hammerer-Lercher, Angelika
    Kamstrup, Pia R.
    Kolovou, Genovefa
    Kronenberg, Florian
    Mora, Samia
    Pulkki, Kari
    Remaley, Alan T.
    Rifai, Nader
    Ros, Emilio
    Stankovic, Sanja
    Stavljenic-Rukavina, Ana
    Sypniewska, Grazyna
    Watts, Gerald F.
    Wiklund, Olov
    Laitinen, Paivi
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (04) : 496 - 517
  • [8] Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1093/eurheartj/ehz455, 10.1016/j.atherosclerosis.2019.08.014]
  • [9] Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation Insights From the FOURIER Trial
    Martin, Seth S.
    Giugliano, Robert P.
    Murphy, Sabina A.
    Wasserman, Scott M.
    Stein, Evan A.
    Ceska, Richard
    Lopez-Miranda, Jose
    Georgiev, Borislav
    Lorenzatti, Alberto J.
    Tikkanen, Matti J.
    Sever, Peter S.
    Keech, Anthony C.
    Pedersen, Terje R.
    Sabatine, Marc S.
    [J]. JAMA CARDIOLOGY, 2018, 3 (08) : 749 - 753
  • [10] 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease
    Mortensen, Martin Bodtker
    Nordestgaard, Borge Gronne
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (31) : 3005 - 3015
1234